OPKO Health (NASDAQ:OPK) Shares Gap Up – What’s Next?

OPKO Health, Inc. (NASDAQ:OPK)’s stock price gapped up before the market opened on Thursday. The stock had previously closed at $1.37, but opened at $1.65. OPKO Health shares last traded at $1.6750, with a volume of 30,122,967 shares.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of OPKO Health in a research note on Wednesday, July 29th. Zacks Research raised shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $1.55.

OPKO Health Stock Up 18.6%

The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -18.06 and a beta of 1.51. The firm’s 50 day moving average price is $1.51 and its two-hundred day moving average price is $1.37. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The company had revenue of $163.58 million for the quarter, compared to analysts’ expectations of $131.23 million. During the same period in the prior year, the firm earned ($0.19) EPS. OPKO Health’s quarterly revenue was up 4.3% compared to the same quarter last year. Sell-side analysts anticipate that OPKO Health, Inc. will post -0.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OPKO Health

Institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC bought a new stake in OPKO Health in the second quarter valued at approximately $27,000. World Investment Advisors lifted its position in shares of OPKO Health by 63.8% in the fourth quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 25,902 shares during the last quarter. Apella Capital LLC acquired a new stake in shares of OPKO Health in the first quarter valued at approximately $34,000. EP Wealth Advisors LLC bought a new position in shares of OPKO Health during the 2nd quarter worth approximately $45,000. Finally, Diversify Advisory Services LLC bought a new position in shares of OPKO Health during the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions.